Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
50
ICLR Quote, Financials, Valuation and Earnings
Last price:
$188.18
Seasonality move
:
2.54%
Day range:
$181.06 - $184.00
52-week range:
$125.10 - $228.29
Dividend yield:
0%
P/E ratio:
24.63x
P/S ratio:
1.80x
P/B ratio:
1.49x
Volume:
309.6K
Avg. volume:
922.1K
1-year change:
-13.11%
Market cap:
$13.9B
Revenue:
$8.3B
EPS (TTM):
$7.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ICLR
ICON plc
|
$2B | $3.32 | -1.45% | 5% | $206.38 |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$285K | -$0.23 | -80.82% | -75.61% | $7.00 |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte, Inc.
|
$131.7M | $0.39 | 11.04% | 511.28% | $47.50 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ICLR
ICON plc
|
$182.22 | $206.38 | $13.9B | 24.63x | $0.00 | 0% | 1.80x |
|
FONR
FONAR Corp.
|
$18.56 | -- | $116.9M | 16.78x | $0.00 | 0% | 1.13x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$7.50 | $7.00 | $215M | -- | $0.00 | 0% | 45.63x |
|
PRPH
ProPhase Labs, Inc.
|
$0.45 | $13.80 | $1.9M | -- | $0.00 | 0% | 0.31x |
|
VCYT
Veracyte, Inc.
|
$42.10 | $47.50 | $3.3B | 110.91x | $0.00 | 0% | 6.76x |
|
XWEL
XWELL, Inc.
|
$0.46 | -- | $2.7M | -- | $0.00 | 0% | 0.08x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ICLR
ICON plc
|
27.67% | 0.618 | 26.73% | 0.98x |
|
FONR
FONAR Corp.
|
18.59% | 1.184 | 49.09% | 9.64x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-51.52% | -0.710 | 3.29% | 2.57x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | 0.697 | 40.4% | 0.07x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.309 | 1.49% | 5.74x |
|
XWEL
XWELL, Inc.
|
278.04% | 2.325 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ICLR
ICON plc
|
$456M | $258.9M | 4.57% | 6.29% | 12.67% | $351.9M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-$423K | -$7.7M | -1767.73% | -1008.03% | -2950% | -$5.6M |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
ICON plc vs. Competitors
-
Which has Higher Returns ICLR or FONR?
FONAR Corp. has a net margin of 0.12% compared to ICON plc's net margin of 10.25%. ICON plc's return on equity of 6.29% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital ICLRICON plc22.32% $0.03 $12.9B FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About ICLR or FONR?
ICON plc has a consensus price target of $206.38, signalling upside risk potential of 13.26%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that ICON plc has higher upside potential than FONAR Corp., analysts believe ICON plc is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings ICLRICON plc10 8 0 FONRFONAR Corp.0 0 0 -
Is ICLR or FONR More Risky?
ICON plc has a beta of 1.256, which suggesting that the stock is 25.574% more volatile than S&P 500. In comparison FONAR Corp. has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.67700000000001%.
-
Which is a Better Dividend Stock ICLR or FONR?
ICON plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICON plc pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICLR or FONR?
ICON plc quarterly revenues are $2B, which are larger than FONAR Corp. quarterly revenues of $26M. ICON plc's net income of $2.4M is lower than FONAR Corp.'s net income of $2.7M. Notably, ICON plc's price-to-earnings ratio is 24.63x while FONAR Corp.'s PE ratio is 16.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICON plc is 1.80x versus 1.13x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICLRICON plc1.80x 24.63x $2B $2.4M FONRFONAR Corp.1.13x 16.78x $26M $2.7M
-
Which has Higher Returns ICLR or IMDX?
Insight Molecular Diagnostics, Inc. has a net margin of 0.12% compared to ICON plc's net margin of -4174.62%. ICON plc's return on equity of 6.29% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.
Company Gross Margin Earnings Per Share Invested Capital ICLRICON plc22.32% $0.03 $12.9B IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M -
What do Analysts Say About ICLR or IMDX?
ICON plc has a consensus price target of $206.38, signalling upside risk potential of 13.26%. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could fall by -6.67%. Given that ICON plc has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe ICON plc is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICLRICON plc10 8 0 IMDXInsight Molecular Diagnostics, Inc.1 2 0 -
Is ICLR or IMDX More Risky?
ICON plc has a beta of 1.256, which suggesting that the stock is 25.574% more volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.885%.
-
Which is a Better Dividend Stock ICLR or IMDX?
ICON plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICON plc pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICLR or IMDX?
ICON plc quarterly revenues are $2B, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. ICON plc's net income of $2.4M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, ICON plc's price-to-earnings ratio is 24.63x while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICON plc is 1.80x versus 45.63x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICLRICON plc1.80x 24.63x $2B $2.4M IMDXInsight Molecular Diagnostics, Inc.45.63x -- $260K -$10.9M
-
Which has Higher Returns ICLR or PRPH?
ProPhase Labs, Inc. has a net margin of 0.12% compared to ICON plc's net margin of -774.52%. ICON plc's return on equity of 6.29% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital ICLRICON plc22.32% $0.03 $12.9B PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About ICLR or PRPH?
ICON plc has a consensus price target of $206.38, signalling upside risk potential of 13.26%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 30737.99%. Given that ProPhase Labs, Inc. has higher upside potential than ICON plc, analysts believe ProPhase Labs, Inc. is more attractive than ICON plc.
Company Buy Ratings Hold Ratings Sell Ratings ICLRICON plc10 8 0 PRPHProPhase Labs, Inc.0 0 0 -
Is ICLR or PRPH More Risky?
ICON plc has a beta of 1.256, which suggesting that the stock is 25.574% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.559, suggesting its less volatile than the S&P 500 by 155.946%.
-
Which is a Better Dividend Stock ICLR or PRPH?
ICON plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICON plc pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICLR or PRPH?
ICON plc quarterly revenues are $2B, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. ICON plc's net income of $2.4M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, ICON plc's price-to-earnings ratio is 24.63x while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICON plc is 1.80x versus 0.31x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICLRICON plc1.80x 24.63x $2B $2.4M PRPHProPhase Labs, Inc.0.31x -- $883K -$6.8M
-
Which has Higher Returns ICLR or VCYT?
Veracyte, Inc. has a net margin of 0.12% compared to ICON plc's net margin of 14.51%. ICON plc's return on equity of 6.29% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital ICLRICON plc22.32% $0.03 $12.9B VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About ICLR or VCYT?
ICON plc has a consensus price target of $206.38, signalling upside risk potential of 13.26%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 12.83%. Given that ICON plc has higher upside potential than Veracyte, Inc., analysts believe ICON plc is more attractive than Veracyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICLRICON plc10 8 0 VCYTVeracyte, Inc.8 2 1 -
Is ICLR or VCYT More Risky?
ICON plc has a beta of 1.256, which suggesting that the stock is 25.574% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.569%.
-
Which is a Better Dividend Stock ICLR or VCYT?
ICON plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICON plc pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICLR or VCYT?
ICON plc quarterly revenues are $2B, which are larger than Veracyte, Inc. quarterly revenues of $131.9M. ICON plc's net income of $2.4M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, ICON plc's price-to-earnings ratio is 24.63x while Veracyte, Inc.'s PE ratio is 110.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICON plc is 1.80x versus 6.76x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICLRICON plc1.80x 24.63x $2B $2.4M VCYTVeracyte, Inc.6.76x 110.91x $131.9M $19.1M
-
Which has Higher Returns ICLR or XWEL?
XWELL, Inc. has a net margin of 0.12% compared to ICON plc's net margin of -2.87%. ICON plc's return on equity of 6.29% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital ICLRICON plc22.32% $0.03 $12.9B XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About ICLR or XWEL?
ICON plc has a consensus price target of $206.38, signalling upside risk potential of 13.26%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1419.1%. Given that XWELL, Inc. has higher upside potential than ICON plc, analysts believe XWELL, Inc. is more attractive than ICON plc.
Company Buy Ratings Hold Ratings Sell Ratings ICLRICON plc10 8 0 XWELXWELL, Inc.0 0 0 -
Is ICLR or XWEL More Risky?
ICON plc has a beta of 1.256, which suggesting that the stock is 25.574% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.585%.
-
Which is a Better Dividend Stock ICLR or XWEL?
ICON plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICON plc pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICLR or XWEL?
ICON plc quarterly revenues are $2B, which are larger than XWELL, Inc. quarterly revenues of $7.3M. ICON plc's net income of $2.4M is higher than XWELL, Inc.'s net income of -$211K. Notably, ICON plc's price-to-earnings ratio is 24.63x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICON plc is 1.80x versus 0.08x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICLRICON plc1.80x 24.63x $2B $2.4M XWELXWELL, Inc.0.08x -- $7.3M -$211K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 5.4% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.78% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 8.96% over the past day.
